scholarly journals Evaluation of the Biostar Chlamydia OIA Assay with Specimens from Women Attending a Sexually Transmitted Disease Clinic

1998 ◽  
Vol 36 (8) ◽  
pp. 2183-2186 ◽  
Author(s):  
Mitchell S. Pate ◽  
Paula B. Dixon ◽  
Kim Hardy ◽  
Mark Crosby ◽  
E. W. Hook
Keyword(s):  
Cell Culture ◽  
Chlamydia Trachomatis ◽  
Fluorescent Antibody ◽  
Transmitted Disease ◽  
The United States ◽  
Chlamydia Screening ◽  
Test Results ◽  
Screening Assay ◽  
Predictive Values ◽  
Sexually Transmitted

Chlamydia trachomatis infections are the most prevalent sexually transmitted diseases (STDs) in the United States. In acute-care settings such as clinics and emergency rooms, a desirable chlamydia screening assay should exhibit good sensitivity and good specificity and should provide test results while the patient is still present. The Biostar Chlamydia OIA (Biostar, Inc., Boulder, Colo.) is an optical immunoassay (OIA) that provides test results in less than 30 min and that uses a test format that allows office-based testing. This assay is performed entirely at room temperature without the need for rotators or other specialized equipment. The goal of this study was to compare the performance of the Biostar Chlamydia OIA for the detection of C. trachomatis with the performance of cell culture, direct fluorescent-antibody (DFA) assay (Syva MicroTrak; Syva Co., Palo Alto, Calif.), and PCR (Roche Amplicor Chlamydia trachomatis; Roche, Branchburg, N.J.) for the detection ofC. trachomatis infections in women attending an urban STD clinic. For calculations of relative test performance (sensitivity, specificity, and positive and negative predictive values), patient specimens that yielded positive results by two or more of the four assays (cell culture, DFA assay, PCR, and OIA) were classified as “true infections.” By these criteria, 42 of 306 total specimens were classified as positive for C. trachomatis (positive prevalence, 13.7%), 11 (3.6%; 10 by PCR and 1 by DFA assay) were positive by a single assay, and 253 (82.7%) were negative by all four tests. All culture-positive specimens were also positive by at least one other assay. Among the culture-negative specimens, 14 (5%) specimens were positive by two of the three non-culture-based assays used. By using the criterion that positivity by at least two of the tests indicated a true infection, the relative sensitivities were as follows: culture and PCR, 92.9% each; Biostar Chlamydia OIA, 73.8%; and DFA assay, 59.5%.

scholarly journals Reaching Youth With Sexually Transmitted Disease Testing

2014 ◽  
Vol 20 (2) ◽  
pp. 116-138 ◽  
Author(s):  
Allison L. Friedman ◽  
Allison Bozniak ◽  
Jessie Ford ◽  
Ashley Hill ◽  
Kristina Olson ◽  
...  
Keyword(s):  
Sexual Health ◽  
Sexually Transmitted Disease ◽  
New Technologies ◽  
Low Cost ◽  
Local Level ◽  
Transmitted Disease ◽  
The United States ◽  
Chlamydia Screening ◽  
Sexually Transmitted ◽  
Disease Testing

Nine programs were funded across eight states in the United States to customize, implement, and evaluate local campaigns in support of the national Get Yourself Tested ( GYT) campaign. Each program promoted chlamydia screening and treatment/referral to sexually active young women (aged 15–25 years) and their partners through accessible, free, or low-cost services. This article documents the strategies and outcomes of these local GYT campaigns, highlighting the diversity in which a national sexual health campaign is implemented at the local level and identifying challenges and successes. Nearly all ( n = 7) programs involved target audience members in campaign development/implementation. Youth were linked to free or low-cost sexually transmitted disease testing through community centers, high schools and colleges, community and clinic events; online or text-based ordering of test kits; and community pickup locations. Sites used a combination of traditional and new media, on-the-ground activities, promotional products, and educational and social events to promote testing. With the exception of one site, all sites reported increases in the number of persons tested for chlamydia during campaign implementation, compared to baseline. Increases ranged from 0.5% to 128%. Successes included development of local partnerships, infrastructure, and capacity; use of peer leaders and involvement; and opportunities to explore new innovations. Challenges included use of social media/new technologies, timing constraints, limited organizational and evaluation capacity, and unforeseen delays/setbacks. Each of these issues is explored, along with lessons learned, with intent to inform future sexual health promotion efforts.

scholarly journals Performance of the Syva Direct Fluorescent Antibody Assay for Chlamydia in a Low-Prevalence Population

1993 ◽  
Vol 1 (1) ◽  
pp. 2-6 ◽  
Author(s):  
Mark B. Reedy ◽  
Patricia J. Sulak ◽  
William B. McCombs III ◽  
Thomas J. Kuehl
Keyword(s):  
Tissue Culture ◽  
Fluorescent Antibody ◽  
Transmitted Disease ◽  
The United States ◽  
Current Data ◽  
Chlamydia Infection ◽  
Culture Methods ◽  
Predictive Values ◽  
Direct Fluorescent Antibody ◽  
Low Prevalence

Chlamydia trachomatisis the most common reportable sexually transmitted disease (STD) in the United States. In the 1980s, rapid diagnostic tests for chlamydia began to replace more cumbersome tissue culture methods. Current data on rapid antigen detection assays demonstrate acceptable sensitivity, specificity, and predictive values in populations with a high prevalence of chlamydia. Few studies report the performance of these assays in a low-prevalence obstetric and gynecologic (Ob/Gyn) population, This study compares the most commonly used direct fluorescent antibody (DFA) assay (Syva Microtrak) with tissue culture (TC) in a low-prevalence population. Endocervical specimens (775) were tested from women at risk for chlamydia infection, and the prevalence was found to be 7.7%. The DFA assay demonstrated a sensitivity of 80% and a specificity of 97% compared with TC. The positive and negative predictive values were 72% and 98%, respectively. The results of this study indicate that the Syva DFA assay lacks the sensitivity and positive predictive value for routine use in Ob/Gyn populations with a lowprevalence ofC. trachomatis.

Evaluation of an Enzyme Immunoassay for Detection of Chlamydia Trachomatis in Urogenital Specimens

1990 ◽  
Vol 1 (1) ◽  
pp. 49-52 ◽  
Author(s):  
J A J W Kluytmans ◽  
A H van der Willigen ◽  
B Y M van Heyst ◽  
W I van der Meyden ◽  
E Stolz ◽  
...  
Keyword(s):  
Cell Culture ◽  
Chlamydia Trachomatis ◽  
Transmitted Disease ◽  
Rapid Test ◽  
University Hospital ◽  
Male Population ◽  
Sexually Transmitted ◽  
High Risk Populations ◽  
Male Patients ◽  
The University

Chlamydiazyme® (Abbott), an enzyme-linked immunoassay (EIA), was evaluated using cell culture on Hela 229 cells as the method of reference. Samples were acquired from 611 female and 280 male patients attending the outpatient clinic for sexually transmitted disease at the University Hospital in Rotterdam, The Netherlands. The prevalences of chlamydia culture-positive female and male patients were 7.8% and 14.4% respectively. The overall sensitivity and specificity values of the EIA were respectively 68.1% and 95.8% in the female and 92.1% and 92.0% in the male population. Samples which were culture-negative but EIA-positive were re-examined by a second direct test (IDEA; Boots Celltech). If the samples from 12 females and 11 males which were negative on culture but positive with both direct tests are considered as failures of cell culture, the sensitivity of the EIA in females almost equalled cell culture (74.6% versus 79.9%) and in males was even higher (93.9% versus 77.6%). Serotyping of the cultured strains revealed that all serovars of Chlamydia trachomatis occurring in this study could be detected by the EIA. The EIA offers a relatively simple and rapid test for diagnosis of C. trachomatis infections in high-risk populations.

scholarly journals Detection of Chlamydia trachomatis by the Gen-Probe AMPLIFIED Chlamydia Trachomatis Assay (AMP CT) in Urine Specimens from Men and Women and Endocervical Specimens from Women

1998 ◽  
Vol 36 (2) ◽  
pp. 391-394 ◽  
Author(s):  
Kimberly A. Crotchfelt ◽  
Barbara Pare ◽  
Charlotte Gaydos ◽  
Thomas C. Quinn
Keyword(s):  
Chlamydia Trachomatis ◽  
Fluorescent Antibody ◽  
Transmitted Disease ◽  
23S Rrna ◽  
Baltimore City ◽  
Men And Women ◽  
Sexually Transmitted ◽  
Antibody Staining ◽  
Female Urine ◽  
Urine Specimens

Molecular biology-based amplification methods are significantly more sensitive than other methods for the detection of Chlamydia trachomatis. The performance characteristics of the new Gen-Probe AMPLIFIED Chlamydia Trachomatis Assay (AMP CT) with endocervical and urine specimens were compared to those of culture for patients attending two Baltimore City sexually transmitted disease clinics and a clinic for adolescents. AMP CT uses transcription-mediated amplification (TMA) and hybridization protection assay procedures to qualitatively detect C. trachomatis by targeting a 23S rRNA. Discrepant results between culture-negative and AMP CT-positive specimens were resolved by direct fluorescent-antibody staining of sedimented culture transport medium for elementary bodies and by TMA with 16S rRNA as a target. Following discrepant analysis, for 480 female urine specimens AMP CT had a sensitivity of 93.8% and a specificity of 100%. For 464 male urine specimens, the resolved sensitivity and specificity of AMP CT were 95.6 and 98.7%, respectively. For the 479 endocervical swab specimens the sensitivity of AMP CT was 100% and the specificity was 99.5%. Resolved culture sensitivities of AMP CT for female and male swab specimens were 52.3 and 58.9%, respectively. These results demonstrate that AMP CT is highly sensitive for the detection of C. trachomatis in endocervical specimens and in urine specimens from men and women.

scholarly journals Performance of the Gen-Probe AMPLIFIED Chlamydia Trachomatis Assay in Detecting Chlamydia trachomatis in Endocervical and Urine Specimens from Women and Urethral and Urine Specimens from Men Attending Sexually Transmitted Disease and Family Planning Clinics

1998 ◽  
Vol 36 (11) ◽  
pp. 3230-3233 ◽  
Author(s):  
Dennis V. Ferrero ◽  
Holly N. Meyers ◽  
Diane E. Schultz ◽  
Stephen A. Willis
Keyword(s):  
Chlamydia Trachomatis ◽  
Sexually Transmitted Disease ◽  
Fluorescent Antibody ◽  
Transmitted Disease ◽  
Nucleic Acid Hybridization ◽  
Protection Assay ◽  
Men And Women ◽  
Sexually Transmitted ◽  
Direct Fluorescent Antibody ◽  
Urine Specimens

The Gen-Probe AMPLIFIED Chlamydia Trachomatis Assay (AMP CT) uses transcription-mediated amplification and hybridization protection assay procedures to qualitatively detect Chlamydia trachomatisrRNA in urine, endocervical swab, and urethral specimens. The performance of the AMP CT was compared to that of cell culture for endocervical swab and urine specimens from women and urethral and urine specimens from men. Analysis of specimens with discrepant results was performed by a combination of reculture, direct fluorescent-antibody (DFA) staining of specimen sediment, and amplification which targeted a different chlamydial rRNA. A total of 800 urine samples were tested by the AMP CT (607 from women and 193 from men), and 7.1% were positive for C. trachomatis, with a sensitivity of 91.2% and a specificity of 99.6% upon discrepant analysis. A total of 926 swab specimens were tested by culture and AMP CT (717 endocervical swab specimens and 209 urethral swab specimens from men), and 7.7% were positive for C. trachomatis, with a sensitivity and specificity of 100% upon discrepant analysis. The AMP CT is a sensitive and specific nucleic acid hybridization assay for the detection of C. trachomatis in endocervical swab specimens from women, urethral swab specimens from men, and urine specimens from men and women.

Sign in / Sign up

Export Citation Format

Share Document